Cargando…

Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()

BACKGROUND: Barrett's esophagus metaplasia is the key precursor lesion of esophageal adenocarcinoma. The aim of this study was to find a subset of markers that may allow the identification of patients at risk for esophageal adenocarcinoma, and to determine genes differentially expressed in esop...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yiyang, Wang, Qing, Gonzalez Lopez, Adrian, Anders, Mario, Malfertheiner, Peter, Vieth, Michael, Kemmner, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002392/
https://www.ncbi.nlm.nih.gov/pubmed/29223109
http://dx.doi.org/10.1016/j.tranon.2017.10.003
_version_ 1783332193352810496
author Dai, Yiyang
Wang, Qing
Gonzalez Lopez, Adrian
Anders, Mario
Malfertheiner, Peter
Vieth, Michael
Kemmner, Wolfgang
author_facet Dai, Yiyang
Wang, Qing
Gonzalez Lopez, Adrian
Anders, Mario
Malfertheiner, Peter
Vieth, Michael
Kemmner, Wolfgang
author_sort Dai, Yiyang
collection PubMed
description BACKGROUND: Barrett's esophagus metaplasia is the key precursor lesion of esophageal adenocarcinoma. The aim of this study was to find a subset of markers that may allow the identification of patients at risk for esophageal adenocarcinoma, and to determine genes differentially expressed in esophageal squamous cell carcinoma. METHODS: Laser capture microdissection technique was applied to procure cells from defined regions. Genome-wide RNA profiling was performed on esophageal adenocarcinoma (n = 21), Barrett's esophagus (n = 20), esophageal squamous carcinoma (n = 9) and healthy esophageal biopsies (n = 18) using the Affymetrix Human Genome U133plus 2.0 array. Microarray results were validated by quantitative real-time polymerase chain reaction in a second and independent cohort and by immunohistochemistry of two putative markers in a third independent cohort. RESULTS: Through unsupervised hierarchical clustering and principal component analysis, samples were separated into four distinct groups that match perfectly with histology. Many genes down-regulated in esophageal cancers belong to the epidermal differentiation complex or the related GO-group “cornified envelope” of terminally differentiated keratinocytes. Similarly, retinol metabolism was strongly down-regulated. Genes showing strong overexpression in esophageal carcinomas belong to the GO groups extracellular region /matrix such as MMP1, CTHRC1, and INHBA. According to an analysis of genes strongly up-regulated in both esophageal adenocarcinoma and Barrett's esophagus, REG4 might be of particular interest as an early marker for esophageal adenocarcinoma. CONCLUSIONS: Our study provides high quality data, which could serve for identification of potential biomarkers of Barrett's esophagus at risk of esophageal adenocarcinoma progression.
format Online
Article
Text
id pubmed-6002392
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-60023922018-06-18 Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()() Dai, Yiyang Wang, Qing Gonzalez Lopez, Adrian Anders, Mario Malfertheiner, Peter Vieth, Michael Kemmner, Wolfgang Transl Oncol Original article BACKGROUND: Barrett's esophagus metaplasia is the key precursor lesion of esophageal adenocarcinoma. The aim of this study was to find a subset of markers that may allow the identification of patients at risk for esophageal adenocarcinoma, and to determine genes differentially expressed in esophageal squamous cell carcinoma. METHODS: Laser capture microdissection technique was applied to procure cells from defined regions. Genome-wide RNA profiling was performed on esophageal adenocarcinoma (n = 21), Barrett's esophagus (n = 20), esophageal squamous carcinoma (n = 9) and healthy esophageal biopsies (n = 18) using the Affymetrix Human Genome U133plus 2.0 array. Microarray results were validated by quantitative real-time polymerase chain reaction in a second and independent cohort and by immunohistochemistry of two putative markers in a third independent cohort. RESULTS: Through unsupervised hierarchical clustering and principal component analysis, samples were separated into four distinct groups that match perfectly with histology. Many genes down-regulated in esophageal cancers belong to the epidermal differentiation complex or the related GO-group “cornified envelope” of terminally differentiated keratinocytes. Similarly, retinol metabolism was strongly down-regulated. Genes showing strong overexpression in esophageal carcinomas belong to the GO groups extracellular region /matrix such as MMP1, CTHRC1, and INHBA. According to an analysis of genes strongly up-regulated in both esophageal adenocarcinoma and Barrett's esophagus, REG4 might be of particular interest as an early marker for esophageal adenocarcinoma. CONCLUSIONS: Our study provides high quality data, which could serve for identification of potential biomarkers of Barrett's esophagus at risk of esophageal adenocarcinoma progression. Neoplasia Press 2017-12-18 /pmc/articles/PMC6002392/ /pubmed/29223109 http://dx.doi.org/10.1016/j.tranon.2017.10.003 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Dai, Yiyang
Wang, Qing
Gonzalez Lopez, Adrian
Anders, Mario
Malfertheiner, Peter
Vieth, Michael
Kemmner, Wolfgang
Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title_full Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title_fullStr Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title_full_unstemmed Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title_short Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths()()
title_sort genome-wide analysis of barrett's adenocarcinoma. a first step towards identifying patients at risk and developing therapeutic paths()()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002392/
https://www.ncbi.nlm.nih.gov/pubmed/29223109
http://dx.doi.org/10.1016/j.tranon.2017.10.003
work_keys_str_mv AT daiyiyang genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT wangqing genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT gonzalezlopezadrian genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT andersmario genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT malfertheinerpeter genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT viethmichael genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths
AT kemmnerwolfgang genomewideanalysisofbarrettsadenocarcinomaafirststeptowardsidentifyingpatientsatriskanddevelopingtherapeuticpaths